News Immunocore hires Lilly's Hotchkiss as chief commercial offic... UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
News Immunocore and GSK pick third cancer immunotherapy target Immunocore, one of UK biotech's brightest hopes, has selected a third target as part of its immuno-oncology partnership with GlaxoSmithKline.
News Immunocore's T-cell therapy could provide HIV cure Treatment promises cure by reactivating immune cells to kill latent HIV-infected cells.
R&D T-cell specialist Immunocore raises $320m in private finance Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.
Cancer Lilly and Immunocore collaborate on novel cancer therapies Eli Lilly and Immunocore have agreed to collaborate on R&D into novel T-cell-based cancer therapies.
Oncology BioNTech’s ASCO 2025 oncology advances: New data on bispecif... At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face